4 completed, 2 active not recruiting, 2 unknown, 2 withdrawn. 7 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Unknown 2, Withdrawn 2 |
| Phase 2 | 7 | Active not recruiting 2, Completed 2, Unknown 2, Withdrawn 1 |
Follow Galecto Biotech AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia GB3226 - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Withdrawn | Galecto Biotech AB | 2026-06-10 | 2026-07-06 | |
| GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma GB1211, Pembrolizumab, Placebo - Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Providence Health & Services | 12 | 2024-02-29 | 2026-09-22 |
| A Study to Compare Pharmacokinetics of GB1211 GB1211 - Pharmacokinetics | Phase 1 | Completed | Galecto Biotech AB | 13 | 2023-01-03 | 2023-09-01 |
| A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). GB1211, Placebo, Atezolizumab - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Galecto Biotech AB | 88 | 2022-03-15 | 2024-04-12 |
| A Single and Repeat Dose Trial in Participants With Hepatic Impairment GB1211, Placebo - Hepatic Impairment | Phase 1 / Phase 2 | Unknown | Galecto Biotech AB | 54 | 2021-09-09 | 2023-05-11 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis GB2064 - Myelofibrosis | Phase 2 | Active not recruiting | Galecto Biotech AB | 21 | 2021-06-09 | 2024-04-03 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis GB1211, Placebo - Non-alcoholic Steatohepatitis (NASH) | Phase 1 / Phase 2 | Withdrawn | Galecto Biotech AB | 2021-03-01 | 2021-02-04 | |
| A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) GB0139, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Completed | Galecto Biotech AB | 172 | 2019-02-19 | 2024-05-22 |
| A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects GB1211, Placebo - Safety and Tolerability | Phase 1 | Completed | Galecto Biotech AB | 78 | 2019-01-14 | 2021-03-17 |
| RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Inhaled TD139, Placebo - Idiopathic Pulmonary Fibrosis | Phase 1 / Phase 2 | Completed | Galecto Biotech AB | 60 | 2014-09-01 | 2023-11-07 |
Liver Cirrhosis (3) · Idiopathic Pulmonary Fibrosis (2) · Non-alcoholic Fatty Liver Disease (2) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Myeloid, Acute (1) · Melanoma (1) · Primary Myelofibrosis (1) · Squamous Cell Carcinoma of Head and Neck (1)
GB-0139 (1) · atezolizumab (1) · pembrolizumab (1)
United Kingdom (3) · United States (3) · Australia (2) · France (2) · Germany (2) · Italy (2) · Poland (2) · Spain (2) · Belgium (1) · Bulgaria (1) · Canada (1) · Georgia (1) · Ireland (1) · Israel (1) · Netherlands (1)
Brendan D. Curti, MD (1) · Dr Ashley Brooks, MBChB (1) · Dr Bertil Lindmark MD PHD, Chief Medical Officer (1) · Francois Ghiringhelli, MD (1) · Michael Charlton, MD (1) · Richard F Schlenk, MD (1) · Toby Maher, MD (1) · Toby Maher, MD, PhD (1) · Zahariy Krastev, MD (1)
PMID 33072090, PMID 33214209, PMID 35120836, PMID 36914828, PMID 39167148, PMID 39358661
2018 (2)